BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...builds machine-learning algorithms that analyze digitized pathology images for diagnostics. The technology was developed at Memorial Sloan Kettering Cancer Center...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...United Therapeutics Corp. (NASDAQ:UTHR) for $105 million. Memorial Sloan Kettering Cancer Center...
...Oncology LLC Zai Lab Ltd. United Therapeutics Corp. Y-mAbs Therapeutics Inc. Memorial Sloan Kettering Cancer Center United...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...T cell platform and technologies licensed from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...could lead to full approval of the humanized mAb against GD2. Y-mAbs licensed Danyelza from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
...of drugs.” Steve Usdin U.S. Food and Drug Administration (FDA) CMS Memorial Sloan Kettering Cancer Center Merck...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...most recently as physician-in-chief and CMO at Memorial Sloan Kettering Cancer Center...
...growth factor Karen Tkach Tuzman AstraZeneca plc Daiichi Sankyo Co. Ltd. Memorial Sloan Kettering Cancer Center q&a cancer...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...translational research capabilities, and collaborations with academic medical centers such as Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center...
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...University, the University of California San Francisco, Memorial Sloan Kettering Cancer Center...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Driehaus and BVF had also invested in Loxo. Leland said the company, in collaboration with Memorial Sloan Kettering Cancer Center...
...NASDAQ:MACK) Disease focus: Cancer Clinical status: Phase II Founded: 2019 by Shawn Leland University collaborators: Memorial Sloan Kettering Cancer Center...
BioCentury | Jul 11, 2020
Product Development

Gilead’s RWD comparison for remdesivir is ‘not in the same league of evidence’ as controlled studies, says Bach

...0.22, 0.68, p=0.001). Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
Items per page:
1 - 10 of 687
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...builds machine-learning algorithms that analyze digitized pathology images for diagnostics. The technology was developed at Memorial Sloan Kettering Cancer Center...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...United Therapeutics Corp. (NASDAQ:UTHR) for $105 million. Memorial Sloan Kettering Cancer Center...
...Oncology LLC Zai Lab Ltd. United Therapeutics Corp. Y-mAbs Therapeutics Inc. Memorial Sloan Kettering Cancer Center United...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...T cell platform and technologies licensed from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...could lead to full approval of the humanized mAb against GD2. Y-mAbs licensed Danyelza from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
...of drugs.” Steve Usdin U.S. Food and Drug Administration (FDA) CMS Memorial Sloan Kettering Cancer Center Merck...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...most recently as physician-in-chief and CMO at Memorial Sloan Kettering Cancer Center...
...growth factor Karen Tkach Tuzman AstraZeneca plc Daiichi Sankyo Co. Ltd. Memorial Sloan Kettering Cancer Center q&a cancer...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...translational research capabilities, and collaborations with academic medical centers such as Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center...
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...University, the University of California San Francisco, Memorial Sloan Kettering Cancer Center...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Driehaus and BVF had also invested in Loxo. Leland said the company, in collaboration with Memorial Sloan Kettering Cancer Center...
...NASDAQ:MACK) Disease focus: Cancer Clinical status: Phase II Founded: 2019 by Shawn Leland University collaborators: Memorial Sloan Kettering Cancer Center...
BioCentury | Jul 11, 2020
Product Development

Gilead’s RWD comparison for remdesivir is ‘not in the same league of evidence’ as controlled studies, says Bach

...0.22, 0.68, p=0.001). Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
Items per page:
1 - 10 of 687